Related Experiment Video
Updated: Jun 28, 2026
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
The effect of interferon beta-1b on size of short-lived enhancing lesions in patients with multiple sclerosis
Deeya Gaindh1, Neal Jeffries, Joan Ohayon
1Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, 10 Center Drive, Bethesda, Maryland 20892, USA.
Background:
Contrast enhancing lesions (CELs) in MRI represent inflammatory events in multiple sclerosis (MS). IFN-beta-1b decreases the formation of CELs. However, the ability of IFN-beta-1b to reduce the size of CELs arising during therapy has not been extensively investigated.
Methods:
Thirty patients with relapsing-remitting (RR) MS were followed for a 3-month pre-therapy phase then for a 6-month therapy phase during which treatment with IFN-beta-1b at a dosage of 250 microg subcutaneously injected every other day was employed. Each patient underwent monthly clinical and MRI examinations. For all patients, CELs were identified on postcontrast T1-weighted MRIs. CEL number, size, and volume were computed using Medx software.
Results:
The average number and total lesion volume of CELs visible during the therapy phase were significantly lower than the number and total lesion volume of CELs observed in the pre-therapy phase. However, there was no significant reduction between pre-therapy and therapy phases in the mean size of individual lesions arising during the respective phases.
Conclusions:
Since size of CELs has been related to severity of tissue damage, the lack of size decrease during therapy suggested a limited therapeutic effect of IFN-beta-1b if a blood-brain barrier breakdown has occurred.
Insights
Interferon beta-1b treatment reduced the number and volume of contrast-enhancing lesions (CELs) in multiple sclerosis (MS) patients. However, it did not significantly decrease the size of individual CELs, suggesting limited effects on established tissue damage.
Area of Science:
- Neuroimmunology
- Radiology
- Clinical Therapeutics
Background:
- Contrast-enhancing lesions (CELs) on MRI indicate active inflammation in multiple sclerosis (MS).
- Interferon beta-1b (IFN-beta-1b) is known to reduce the formation of new CELs.
- The impact of IFN-beta-1b on the size of existing CELs during treatment requires further investigation.
Purpose of the Study:
- To evaluate the effect of IFN-beta-1b on the size of contrast-enhancing lesions (CELs) in patients with relapsing-remitting multiple sclerosis (RRMS).
- To assess whether IFN-beta-1b therapy influences the size of active inflammatory lesions in MS.
Main Methods:
- A cohort of 30 RRMS patients was monitored for 3 months pre-therapy and 6 months during IFN-beta-1b treatment (250 mcg subcutaneously every other day).
- Monthly clinical and MRI assessments were performed, with CELs identified on postcontrast T1-weighted MRI scans.
- CEL number, size, and volume were quantified using Medx software.
Main Results:
- A significant reduction in the average number and total volume of CELs was observed during the IFN-beta-1b therapy phase compared to the pre-therapy phase.
- No statistically significant decrease was found in the mean size of individual CELs between the pre-therapy and therapy phases.
- This indicates that while IFN-beta-1b may reduce lesion formation, it does not effectively shrink existing lesions.
Conclusions:
- The lack of reduction in CEL size suggests that IFN-beta-1b may have a limited therapeutic effect once blood-brain barrier breakdown has occurred.
- CEL size is correlated with the severity of neurological tissue damage in MS.
- Further research is needed to understand the full therapeutic potential of IFN-beta-1b in managing MS-related inflammation and damage.
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
01:19Multiple Sclerosis l: Introduction